Literature DB >> 12165862

Localization of deletion to a 300 Kb interval of chromosome 11q13 in cervical cancer.

Eri S Srivatsan1, Rita Chakrabarti, Kayvan Zainabadi, Svetlana D Pack, Payam Benyamini, Marc S Mendonca, Pok Kwan Yang, Kevin Kang, Daria Motamedi, Mark P Sawicki, Zhengping Zhuang, Rachel A Jesudasan, Ulla Bengtsson, Chi Sun, Bruce A Roe, Eric J Stanbridge, Sharon P Wilczynski, J Leslie Redpath.   

Abstract

Previous molecular genetic studies on HeLa cell (a cervical cancer cell line) derived non-tumorigenic and tumorigenic hybrids have localized a tumor suppressor gene to the long arm of chromosome 11. Analysis of cervical cancer cell lines using chromosome 11 specific probes showed deletion and translocation of 11q13 sequences in five out of eight cell lines. Fluorescence in situ hybridization (FISH), using 11q13 specific probes, has shown interstitial deletion of 11q13 sequences in the HeLa cells. In order to determine whether 11q13 deletions occur in primary cervical tumors, we analysed 36 tumors using 20 different microsatellite and RFLP markers. Semi automated fluorescein based allelotyping was performed to identify loss of heterozygosity (LOH) in tumors. The results showed allelic loss in 17 (47%) tumors. Three different regions of loss, one near MEN1, the second near D11S913, and the third near INT2 locus were observed. The smallest region of deletion overlap at the D11S913 locus was localized to a 300 Kb distance between D11S4908 and D11S5023. Fluorescence in situ hybridization (FISH), using 11q13 specific cosmid and BAC (bacterial artificial chromosome) probes, confirmed allelic deletion in the tumors. PCR analysis further identified homozygous deletion of 11q13 sequences in a primary tumor, in HeLa cells and in two HeLa cell derived tumorigenic hybrid cell lines. The homozygous deletion in the cell lines was mapped to a 5.7 kb sequence of 11q13. We hypothesize therefore that a putative cervical cancer tumor suppressor gene exists within the 300 kb of chromosome 11q13.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165862     DOI: 10.1038/sj.onc.1205698

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  A rare eicosanoid precursor analogue, sciadonic acid (5Z,11Z,14Z-20:3), detected in vivo in hormone positive breast cancer tissue.

Authors:  H G Park; J Y Zhang; C Foster; D Sudilovsky; D A Schwed; J Mecenas; S Devapatla; P Lawrence; K S D Kothapalli; J T Brenna
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2018-05-16       Impact factor: 4.006

2.  One in four individuals of African-American ancestry harbors a 5.5kb deletion at chromosome 11q13.1.

Authors:  Kayvan Zainabadi; Anuja V Jain; Frank X Donovan; David Elashoff; Nagesh P Rao; Vundavalli V Murty; Settara C Chandrasekharappa; Eri S Srivatsan
Journal:  Genomics       Date:  2014-01-10       Impact factor: 5.736

3.  Deletion in chromosome 11 and Bcl-1/Cyclin D1 alterations are independently associated with the development of uterine cervical carcinoma.

Authors:  Ratnesh Kumar Singh; Santanu Dasgupta; Nilanjana Bhattacharya; Neelanjana Chunder; Ranjit Mondal; Anup Roy; Syamsundar Mandal; Susanta Roychowdhury; Chinmay Kumar Panda
Journal:  J Cancer Res Clin Oncol       Date:  2005-03-15       Impact factor: 4.553

4.  Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer.

Authors:  Mysore S Veena; Grant Lee; Daniel Keppler; Marc S Mendonca; J Leslie Redpath; Eric J Stanbridge; Sharon P Wilczynski; Eri S Srivatsan
Journal:  Genes Chromosomes Cancer       Date:  2008-09       Impact factor: 5.006

5.  Dysregulation of hsa-miR-34a and hsa-miR-449a leads to overexpression of PACS-1 and loss of DNA damage response (DDR) in cervical cancer.

Authors:  Mysore S Veena; Santanu Raychaudhuri; Saroj K Basak; Natarajan Venkatesan; Parameet Kumar; Roopa Biswas; Rita Chakrabarti; Jing Lu; Trent Su; Marcus Gallagher-Jones; Marco Morselli; Haiqing Fu; Matteo Pellegrini; Theodore Goldstein; Mirit I Aladjem; Matthew B Rettig; Sharon P Wilczynski; Daniel Sanghoon Shin; Eri S Srivatsan
Journal:  J Biol Chem       Date:  2020-10-07       Impact factor: 5.157

6.  The genomic and transcriptomic landscape of a HeLa cell line.

Authors:  Jonathan J M Landry; Paul Theodor Pyl; Tobias Rausch; Thomas Zichner; Manu M Tekkedil; Adrian M Stütz; Anna Jauch; Raeka S Aiyar; Gregoire Pau; Nicolas Delhomme; Julien Gagneur; Jan O Korbel; Wolfgang Huber; Lars M Steinmetz
Journal:  G3 (Bethesda)       Date:  2013-08-07       Impact factor: 3.154

Review 7.  At the crossroads of homoeostasis and disease: roles of the PACS proteins in membrane traffic and apoptosis.

Authors:  Robert T Youker; Ujwal Shinde; Robert Day; Gary Thomas
Journal:  Biochem J       Date:  2009-06-12       Impact factor: 3.857

8.  Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.

Authors:  Ashley G Rivenbark; Chad A Livasy; Courtney E Boyd; Daniel Keppler; William B Coleman
Journal:  Exp Mol Pathol       Date:  2007-04-18       Impact factor: 3.362

9.  FADS2 function loss at the cancer hotspot 11q13 locus diverts lipid signaling precursor synthesis to unusual eicosanoid fatty acids.

Authors:  Woo Jung Park; Kumar S D Kothapalli; Peter Lawrence; J Thomas Brenna
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

10.  The CD44(high) tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression.

Authors:  Saroj K Basak; Mysore S Veena; Scott Oh; Chi Lai; Sitaram Vangala; David Elashoff; Michael C Fishbein; Sanjai Sharma; Nagesh P Rao; Dinesh Rao; Ryan Phan; Eri S Srivatsan; Raj K Batra
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.